panitumumab
takeda,amgen
['improve ', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'rectal', 'colorectal', 'panitumumab']
#asco2022 improve study on intermittent exposure to panitumumab plus chemo in #crcsm is clinically relevant, practice changing, having positive impact on value/cost of care and side effects : highlights of the gastrointestinal cancer - colorectal and anal track by christina wu 